Drug Profile


Alternative Names: NN-1810; NN-1841; NN8717; NovoThirteen; Recombinant factor XIII - Novo Nordisk; Recombinant human factor XIII - Novo Nordisk; rFXIII - Novo Nordisk; rhFactor-XIII - Novo Nordisk; rhFXIII - Novo Nordisk; Tretten

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Factor XIII deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Factor XIII deficiency
  • No development reported Postoperative haemorrhage; Ulcerative colitis

Most Recent Events

  • 03 Dec 2016 Efficacy and adverse events data from the mentor™2 phase III trial in Factor XIII deficiency presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 26 Oct 2015 Novo Nordisk completes a phase III extension trial in Factor XIII deficiency in the USA, Canada, European Union, Israel, Japan and Switzerland (NCT00978380)
  • 09 Mar 2015 Catridecacog is still in phase III trials for Factor XIII deficiency (In infants, In children) in Israel, United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top